OUP user menu

Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis

Ronak Delewi, Alexander Hirsch, Jan G. Tijssen, Volker Schächinger, Wojciech Wojakowski, Jérôme Roncalli, Svend Aakhus, Sandra Erbs, Birgit Assmus, Michal Tendera, R. Goekmen Turan, Roberto Corti, Tim Henry, Patricia Lemarchand, Ketil Lunde, Feng Cao, Heikki V. Huikuri, Daniel Sürder, Robert D. Simari, Stefan Janssens, Kai C. Wollert, Michal Plewka, Stefan Grajek, Jay H. Traverse, Felix Zijlstra, Jan J. Piek
DOI: http://dx.doi.org/10.1093/eurheartj/eht372 989-998 First published online: 11 September 2013


Aims The objective of the present analysis was to systematically examine the effect of intracoronary bone marrow cell (BMC) therapy on left ventricular (LV) function after ST-segment elevation myocardial infarction in various subgroups of patients by performing a collaborative meta-analysis of randomized controlled trials.

Methods and results We identified all randomized controlled trials comparing intracoronary BMC infusion as treatment for ST-segment elevation myocardial infarction. We contacted the principal investigator for each participating trial to provide summary data with regard to different pre-specified subgroups [age, diabetes mellitus, time from symptoms to percutaneous coronary intervention, infarct-related artery, LV end-diastolic volume index (EDVI), LV ejection fraction (EF), infarct size, presence of microvascular obstruction, timing of cell infusion, and injected cell number] and three different endpoints [change in LVEF, LVEDVI, and LV end-systolic volume index (ESVI)].

Data from 16 studies were combined including 1641 patients (984 cell therapy, 657 controls). The absolute improvement in LVEF was greater among BMC-treated patients compared with controls: [2.55% increase, 95% confidence interval (CI) 1.83–3.26, P < 0.001]. Cell therapy significantly reduced LVEDVI and LVESVI (−3.17 mL/m², 95% CI: −4.86 to −1.47, P < 0.001; −2.60 mL/m², 95% CI −3.84 to −1.35, P < 0.001, respectively). Treatment benefit in terms of LVEF improvement was more pronounced in younger patients (age <55, 3.38%, 95% CI: 2.36–4.39) compared with older patients (age ≥55 years, 1.77%, 95% CI: 0.80–2.74, P = 0.03). This heterogeneity in treatment effect was also observed with respect to the reduction in LVEDVI and LVESVI. Moreover, patients with baseline LVEF <40% derived more benefit from intracoronary BMC therapy. LVEF improvement was 5.30%, 95% CI: 4.27–6.33 in patients with LVEF <40% compared with 1.45%, 95% CI: 0.60 to 2.31 in LVEF ≥40%, P < 0.001. No clear interaction was observed between other subgroups and outcomes.

Conclusion Intracoronary BMC infusion is associated with improvement of LV function and remodelling in patients after ST-segment elevation myocardial infarction. Younger patients and patients with a more severely depressed LVEF at baseline derived most benefit from this adjunctive therapy.

  • ST-segment elevation myocardial infarction
  • Bone marrow cells
  • Ventricular function
  • Meta-analysis
View Full Text

Sign In

ESC members click here if your subscription is as an ESC Congress delegete or via your membership link.  Discover if you are an ESC member here.
Note: after sign in you will be redirected to the journal's home page. 'ESC member' will display at the top of the page to indicate you have full access rights for this session.

Otherwise, if your subscription is via OUP, enter your OUP username and password, or select an alternative sign in option below.

Log in through your institution